Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onvansertib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ONSEMBLE
  • Sponsors Cardiff Oncology

    • Most Recent Events

    • 10 Jan 2025 Status changed to completed.
    • 02 May 2024 According to a Cardiff Oncology media release, clinical data from this ONSEMBLE trial presented at the American Association for Cancer Research (AACR).
    • 29 Feb 2024 According to a Cardiff Oncology media release, In August 2023, the company discontinued enrollment in the second-line ONSEMBLE trial to focus on its new lead program in first-line RAS-mutated mCRC.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top